Outcomes in Diabetic Versus Nondiabetic Patients Who Present With Acute Myocardial Infarction and Are Treated With Drug-Eluting Stents

American Journal of Cardiology

Volumn 105, Issue 6, 2010, Pages 819-825

  Syed, Asmir I ^a   Ben Dor, Itsik ^a   Li, Yanlin ^a   Collins, Sara D ^a   Gonzalez, Manuel A ^a   Gaglia, Michael A ^a   Maluenda, Gabriel ^a   Delhaye, Cedric ^a   Wakabayashi, Kohei ^a   Bonello, Laurant ^a   De Labriolle, Axel ^a   Belle, Loic ^a   Torguson, Rebecca ^a   Xue, Zhenyi ^a   Kaneshige, Kimberly ^a   Bernardo, Nelson ^a   Satler, Lowell F ^a   Kent, Kenneth M ^a   Suddath, William O ^a   Pichard, Augusto D ^a   Lindsay, Joseph ^a   Waksman, Ron ^a   more..

^a WASHINGTON HOSPITAL CENTER   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; ARTERY DISEASE; ARTICLE; CARDIOGENIC SHOCK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART ARREST; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; RACE DIFFERENCE; REVASCULARIZATION; SEX DIFFERENCE; STENT THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RETREATMENT; TREATMENT OUTCOME;

EID: 77649179934     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.11.010     Document Type: Article

References (29)

1. In: Ruderman N., Williamson J., and Brownlee M. (Eds). Hyperglycemia, Diabetes, and Vascular Disease (1992), Oxford University Press, New York 21-29
2. Murcia A.M., Hennekens C.H., Lamas G.A., Jiménez-Navarro M., Rouleau J.L., Flaker G.C., Goldman S., Skali H., Braunwald E., and Pfeffer M.A. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 164 (2004) 2273-2279
3. Garg P., Normand S.L., Silbaugh T.S., Wolf R.E., Zelevinsky K., Lovett A., Varma M.R., Zhou Z., and Mauri L. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 118 (2008) 2277-2285
4. Maresta A., Varani E., Balducelli M., Varbella F., Lettieri C., Uguccioni L., Sangiorgio P., Zoccai G.B., and DESSERT Investigators. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol 101 (2008) 1560-1566
5. Lee M.S., Jurewitz D., Zimmer R., Pessegueiro A., Bhatia R., Currier J., Yeatman L., and Tobis J.M. Impact of diabetes and acute coronary syndrome on survival in patients treated with drug-eluting stents. Catheter Cardiovasc Interv 72 (2008) 909-914
6. Zhang Q., Shen J., Zhang R.Y., Qiu J.P., Lu J.D., Zhang Y., Chen Y.H., Zhang J.F., Zhang J.S., Hu J., Yang Z.K., Zheng A.F., Zhang X., and Shen W.F. Outcomes after primary coronary intervention with drug-eluting stent implantation in diabetic patients with acute ST elevation myocardial infarction. Chin Med J [Engl] 120 (2007) 1862-1867
7. Mehran R., Brodie B., Cox D.A., Grines C.L., Rutherford B., Bhatt D.L., Dangas G., Feit F., Ohman E.M., Parise H., Fahy M., Lansky A.J., and Stone G.W. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial: study design and rationale. Am Heart J 156 (2008) 44-56
8. Mauri L., Silbaugh T.S., Garg P., Wolf R.E., Zelevinsky K., Lovett A., Varma M.R., Zhou Z., and Normand S.L.T. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359 (2008) 1330-1342
9. Laarman G.J., Suttorp M.J., Dirksen M.T., van Heerebeek L., Kiemeneij F., Slagboom T., van der Wieken L.R., Tijssen J.G.P., Rensing B.J., and Patterson M. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
10. Spaulding C., Henry P., Teiger E., Beatt K., Bramucci E., Carrié D., Slama M.S., Merkely B., Erglis A., Margheri M., Varenne O., Cebrian A., Stoll H.P., Snead D.B., Bode C., and TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
11. Kastrati A., Dibra A., Spaulding C., Laarman G.J., Menichelli M., Valgimigli M., Di Lorenzo E., Kaiser C., Tierala I., Mehilli J., Seyfarth M., Varenne O., Dirksen M.T., Percoco G., Varricchio A., Pittl U., Syvänne M., Suttorp M.J., Violini R., and Schömig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 (2007) 2706-2713
12. Novack V., Tsyvine D., Cohen D.J., Pencina M., Dubin J., Dehghani H., Kleiman N.S., and Cutlip D.E. Multivessel drug-eluting stenting and impact of diabetes mellitus-a report from the EVENT registry. Catheter Cardiovasc Interv 73 (2008) 874-880
13. Rozenman Y., Sapoznikov D., and Gotsman M.S. Restenosis and progression of coronary disease after balloon angioplasty in patients with diabetes mellitus. Clin Cardiol 23 (2000) 890-894
14. Mathew V., and Holmes D.R. Outcomes in diabetics undergoing revascularization: the long and the short of it. J Am Coll Cardiol 40 (2002) 424-427
15. Mathew V., Gersh B.J., Williams B.A., Laskey W.K., Willerson J.T., Tilbury R.T., Davis B.R., and Holmes Jr. D.R. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 109 (2004) 476-480
16. Mathew V., Wilson S.H., Barsness G.W., Frye R.L., Lennon R., and Holmes D.R. Comparative outcomes of percutaneous coronary interventions in diabetics vs non-diabetics with prior coronary artery bypass grafting. Eur Heart J 23 (2002) 1456-1464
17. Goyal A., Mehta S.R., Gerstein H.C., Díaz R., Afzal R., Xavier D., Zhu J., Pais P., Lisheng L., Kazmi K.A., Zubaid M., Piegas L.S., Widimsky P., Budaj A., Avezum A., and Yusuf S. Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. Am Heart J 157 (2009) 763-770
18. Li L., Guo Y., Guo L., and Gao W. The predictive value of admission glucose for the prognosis of AMI post primary percutaneous coronary intervention. Cardiovasc Revasc Med 7 (2006) 99
19. Iijima R., Mehilli J., Schomig A., and Kasrati A. Drug eluting stents versus Bare metal stents in diabetic patients with acute myocardial infarction: a pooled analysis of individual patient data from 7 randomized trials. Rev Esp Cardiol 62 (2009) 354-364
20. Park D.W., Park S.W., Kima J.S., Nam H.J., Lee J.Y., Kim G.J., Lee S.W., Kim Y.H., Lee C.W., Hong M.K., Kim J.J., and Park S.J. Prognostic influence of diabetes mellitus on long-term clinical outcomes and stent thrombosis after drug-eluting stent implantation in Asian patients. Am J Cardiol 103 (2009) 646-652
21. Meliga E., Garcia-Garcia H.M., Valgimigli M., Chieffo A., Biondi-Zoccai G., Maree A.O., Gonzalo N., Cook S., Cruz-Gonzalez I., Marra S., De Servi S., Palacios I.F., Windecker S., van Domburg R., Colombo A., Sheiban I., and Serruys P.W. Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The diabetes and drug eluting stent for LeFT main registry (D-DELFT). Eurinterv 4 (2008) 77-83
22. Nakazawa G., Finn A.V., Joner M., Ladich E., Kutys R., Mont E.K., Gold H.K., Burke A.P., Kolodgie F.D., and Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118 (2008) 1138-1145
23. Maeng M., Jensen L.O., Galloe A.M., Thayssen P., Christiansen E.H., Hansen K.N., Helqvist S., Botker H.E., Lassen J.F., and Thuesen L. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 103 (2009) 345-349
24. Dibra A., Kastrati A., Mehilli J., Pache J., Schühlen H., von Beckerath N., Ulm K., Wessely R., Dirschinger J., Schömig A., and ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
25. Moss S.C., Lightell Jr. D., Deichmann Jr. R.E., and Woods T.C. Sera from patients with diabetes do not alter the effect of mammalian target of rapamycin inhibition on smooth muscle cell proliferation. J Cardiovasc Pharmacol 53 (2009) 86-89
26. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
27. Lemesle G., Bonello L., de Labriolle A., Maluenda G., Syed A.I., Collins S.D., Ben-Dor I., Torguson R., Kaneshige K., Xue Z., Suddath W.O., Satler L.F., Kent K.M., Lindsay J., Pichard A.D., and Waksman R. Prognostic value of hemoglobin A1c levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol 104 (2009) 41-45
28. Nikolsky E., Mehran R., Turcot D., Aymong E.D., Mintz G.S., Lasic Z., Lansky A.J., Tsounias E., Moses J.W., Stone G.W., Leon M.B., and Dangas G.D. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 94 (2004) 300-305
29. Farkouh M.E., Dangas G., Leon M.B., Smith C., Nesto R., Buse J.B., Cohen D.J., Mahoney E., Sleeper L., King III S., Domanski M., McKinlay S., and Fuster V. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial. Am Heart J 155 (2008) 215-223